Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9002.5000
Address
Unit A8 2A Westall Road Clayton, Victoria (VIC) 3168
Description
Avecho Biotechnology Ltd. engages in the development and commercialization of human and animal products through its proprietary drug delivery system. It operates through the Production and Human Health segments. The Production segment focuses on manufacturing and sale of TPM and Vital ET for the use in drug delivery and cosmetic formulations. The Human Health segment consists of delivery of pharmaceutical products through gels, injectables and patches including conduct of research and development activities. The company was founded by Mark Gregory Kerr on June 19, 1992 and is headquartered in Clayton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.01
Trade Value (12mth)
AU$5,455.00
1 week
-14.29%
1 month
0%
YTD
100%
1 year
50%
All time high
0.42
EPS 3 yr Growth
-47.40%
EBITDA Margin
-425.00%
Operating Cashflow
-$4m
Free Cash Flow Return
-81.30%
ROIC
-64.00%
Interest Coverage
-84.30
Quick Ratio
2.70
Shares on Issue (Fully Dilluted)
3169m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
13 March 25 |
Avecho to present at NWR Virtual Healthcare Conference
×
Avecho to present at NWR Virtual Healthcare Conference |
07 March 25 |
Annual Report 31 December 2024
×
Annual Report 31 December 2024 |
07 March 25 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
04 March 25 |
Licensing Webinar and Presentation
×
Licensing Webinar and Presentation |
03 March 25 |
Avecho & Sandoz Sign Deal to Develop CBD for Insomnia in AUS
×
Avecho & Sandoz Sign Deal to Develop CBD for Insomnia in AUS |
28 February 25 |
Appendix 4E - Preliminary Final Report
×
Appendix 4E - Preliminary Final Report |
28 February 25 |
Trading Halt
×
Trading Halt |
14 February 25 |
Response to ASX Price Query
×
Response to ASX Price Query |
30 January 25 |
December 2024 Quarterly Activities Report & Appendix 4C
×
December 2024 Quarterly Activities Report & Appendix 4C |
02 December 24 |
Notification of cessation of securities - AVE
×
Notification of cessation of securities - AVE |
02 December 24 |
Change of Director's Interest Notice x3
×
Change of Director's Interest Notice x3 |
29 October 24 |
September 2024 Quarterly Activities Report & Appendix 4C
×
September 2024 Quarterly Activities Report & Appendix 4C |
26 August 24 |
Appendix 4D and Half-year Financial Report
×
Appendix 4D and Half-year Financial Report |
30 July 24 |
June 2024 Quarterly Activities Report & Appendix 4C
×
June 2024 Quarterly Activities Report & Appendix 4C |
13 June 24 |
Receipt of R&D Tax Incentive
×
Receipt of R&D Tax Incentive |
30 May 24 |
Chair's Address and CEO Presentation
×
Chair's Address and CEO Presentation |
30 May 24 |
2024 Annual General Meeting Results
×
2024 Annual General Meeting Results |
30 May 24 |
Avecho Biotechnology Limited - Chair's Address and CEO Presentation (AVE-AU)
×
Avecho Biotechnology Limited - Chair's Address and CEO Presentation (AVE-AU) |
30 May 24 |
Avecho Biotechnology Limited - 2024 Annual General Meeting Results (AVE-AU)
×
Avecho Biotechnology Limited - 2024 Annual General Meeting Results (AVE-AU) |
21 May 24 |
Notification of cessation of securities - AVE
×
Notification of cessation of securities - AVE |
21 May 24 |
Avecho Biotechnology Limited - Notification of cessation of securities - AVE (AVE-AU)
×
Avecho Biotechnology Limited - Notification of cessation of securities - AVE (AVE-AU) |
16 May 24 |
First Patient dosed in Phase III insomnia trial
×
First Patient dosed in Phase III insomnia trial |
30 April 24 |
March 2024 Quarterly Activities Report & Appendix 4C
×
March 2024 Quarterly Activities Report & Appendix 4C |
30 April 24 |
Avecho Biotechnology Limited - March 2024 Quarterly Activities Report & Appendix 4C (AVE-AU)
×
Avecho Biotechnology Limited - March 2024 Quarterly Activities Report & Appendix 4C (AVE-AU) |
26 April 24 |
Appointment of New Director
×
Appointment of New Director |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.